Immix Biopharma Reports the Patient Dosing in P-Ib/IIa Trial of IMX-110 + Tislelizumab for the Treatment of Advanced Cancer
Shots:
- The first 2 patients have been dosed in the P-Ib/IIa clinical trial evaluating IMX-110 + Beigene/Novartis’ tislelizumab in patients with advanced solid tumors. Initial clinical data from this combination trial is expected to be released on a rolling basis in H1’2023
- In previous preclinical studies, the combination therapy demonstrated a 50% improvement (63-day median survival) over a 4-drug combination of 2 CT and 2 immunotherapies in the genetic pancreatic cancer mouse model (KPC), in which mice develop their own pancreatic cancer and have an intact immune system (42-day median survival)
- IMX-110 received the ODD from the US FDA in soft tissue sarcoma & RPDD for the treatment of rhabdomyosarcoma
Ref: Immix Biopharma | Image: Immix Biopharma
Related News:- Galapagos to Acquire CellPoint and AboundBio to Advance Cell Therapies for the Treatment of Advanced Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
